Bone marrow test may spare AML patients from extra chemo
NCT ID NCT06323590
First seen May 11, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study looks at whether adults with newly diagnosed acute myeloid leukemia (AML) can safely skip an immediate second round of chemotherapy based on results from a standard mid-induction bone marrow biopsy. Researchers will track how many patients achieve complete remission without acting on the biopsy results. The goal is to see if the biopsy is truly necessary for treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.